Our history

Founded in 2014, aptaTargets spun-out of Aptus Biotech, an aptamer technology platform. aptaTargets started a drug development program collaborating with the Complutense University and the Ramon y Cajal Hospital.

In 2019, aptaTargets started clinical trials, completing the First-in-Human clinical trial in healthy volunteers in Q1 2020. A Phase Ib/IIa trial in acute stroke patients is currently in progress (APRIL study, authorized on July 2020).

Series B round has been raised in 2020, participating Inveready Asset Management and the CDTI (Centre for the Development of Industrial Technology), through the INNVIERTE program.

 

APTATARGETS
clinical-stage biopharmaceutical using aptamer technology for targeting acute indications.
ApTOLL
(Lead-candidate) is a neuroprotective drug for acute ischemic stroke by targeting inflammation in the acute phase.
Targeting indications
where inflammation causes significant damage, including ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.